GUANGZHOU, China, Oct. 13 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME; "China Medicine" or "the Company"), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary supplements, medical devices, and medical formulations in the People's Republic of China ("PRC"), through its wholly-owned U.S subsidiary, Konzern U.S Holding Corporation, announced today that it will participate in the 2008 Natural Products Expo East tradeshow, where it will showcase its new weight loss product called "Bethin." The tradeshow will be held Oct. 15th to Oct. 18th at the Boston Convention & Exhibition Center in Massachusetts. Over 25,000 natural, organic, and health products industry members will participate in this event.
China Medicine's proprietary weight loss product, Bethin, is a food supplement that is designed to promote and adjust fat metabolism, reduce the storage of fat in the body, and prolong endurance during physical exercise. Bethin's active ingredients include L-Carnitine, a special amino acid manufactured by the human body that is essential for the production of energy, and Hydroxycitric acid (HCA), an extract from the fruit of the Garcinia cambogia plant. The Company has filed and obtained all the necessary documentation to launch the new product in the United States.
"We are looking forward to taking part in the upcoming Natural Products Expo East tradeshow in Boston," said Mr. Senshan Yang, Chairman and CEO of China Medicine.
"We anticipate that the introduction of Bethin, our first product sold in U. S. market, will increase our visibility, highlight the benefits of our new product, and allow us to gain a foothold in the international market."
The Company will be exhibiting its product in booth #240. For more information on the tradeshow, please click http://www.expoeast.com .
About China Medicine Corporation
China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and
dietary-supplements. The Company distributes the products to wholesale distributors in 28 provinces, more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feed. For more information visit the Company's website at http://www.chinamedicinecorp.com .
Cautionary Statement
This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
For further information, please contact:
China Medicine Corp
Ms. Huizhen Yu
CFO
Tel: +86-20-8739-1718
Email: konzern08@163.com
Mr. Crocker Coulson
President
CCG InvestorRelations Inc.
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com